MedTrace Logo

THC + CBD and Memory Study

NCT04855526 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-03-17

No results posted yet for this study

Summary

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Conditions

  • Marijuana Use
  • Cannabis Use
  • Cannabis Intoxication

Interventions

DRUG

High THC/No CBD Marihuana

high THC (65 mg THC) and no CBD (0 mg CBD)

DRUG

High THC/High CBD Marihuana

high THC (65 mg THC) and high CBD (50 mg CBD)

DRUG

No THC/No CBD Marihuana

no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Hartford Hospital

    lead OTHER

Principal Investigators

  • Godfrey Pearlson, MD · Hartford Hospital - Olin Neuropsychiatry Research Center; Yale University

  • Alecia Dager, PhD · Hartford Hospital - Olin Neuropsychiatry Research Center; Yale University

  • Michael Stevens, PhD · Hartford Hospital - Olin Neuropsychiatry Research Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-12-30
Completion
2026-12-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855526 on ClinicalTrials.gov